Stakeholder Engagement

Stakeholder Engagement

Our company has established multiple channels for interaction and communication with stakeholders to understand their expectations and concerns regarding the company's sustainable development issues. In addition to responding in a timely manner, these interactions serve as references for promoting the corporate sustainability plan. The company's Sustainability Committee and the Sustainability and Stakeholder Office periodically hold internal meetings to identify and analyze sustainability issues. Conclusions and sustainability outcomes are then discussed with stakeholders, disclosed in the sustainability report, and submitted to the Board of Directors for supervision and guidance. The communication with stakeholders for the year 2024 (ROC Year 113) was reported to the Board of Directors on May 12, 2025.

Stakeholder Contact Information

Main Stakeholder Category	Significance of Stakeholders to the Company and Engagement Activities	Key Issues of Concern	Communication Channels/Frequency
Shareholders/Investors	Shareholders are the investors of the company. The company should protect shareholders' rights and treat all shareholders fairly, ensuring they have the right to fully understand, participate in, and make decisions on major company matters. 1. A summary of the Company’s investor engagement activities for the year 2025 (ROC Year 114) is as follows: Method 1: Investor Conferences (four in total), including: July 16, 2025 – CTBC Securities Investor Conference (virtual) October 28, 2025 – Cathay Securities Biotech Corporate Day (virtual) November 27, 2025 – Uni-President Securities Investor Conference (in-person) December 23, 2025 – Cathay Securities Annual Investor Conference (in-person) Method 2: Phone and Email Communications The Company has established dedicated contact windows for stakeholders. Investors may communicate their feedback at any time via telephone or email. The frequency of communication is on a daily or ad hoc basis. 2. Key Investor Concerns and Company Responses (2025) (1) Core Product Development & Licensing Progress Significant advancements in CX-5461 and CX-4945 Clinical collaboration with BeOne Medicines (CX-5461 + tislelizumab) Ongoing NCI/NIH-sponsored clinical trials (4 studies) Near completion of U.S./Canada clinical trial enrollment; licensing to follow data readout AI-identified new mechanism of CX-4945; pilot collaboration with CellType and flexible options for licensing/co-development/NewCo (2) New Business Development & Management Update Ongoing pipeline expansion with cautious in-licensing evaluation, challenges identified during due diligence (financials, market entry). Acting GM Dr. Jason Huang accelerating core product strategies (new indications/formulations), active evaluation of new opportunities (e.g., photodynamic therapy, immunotherapy for unmet medical needs)	Financial Information Operating Status R&D Progress	Shareholder Meetings/Annually Annual Reports, Financial Statements/Annually Investor Briefings/Annually Investor Email/As needed Spokesperson System/As needed Investor Relations, Mr. Ko jonathanko@senhwabio.com
Government Agencies	Government agencies supervise and audit the company's compliance with various regulations.	Clinical Trial Regulations Information Disclosure Labor Relations Employee Welfare and Corporate Governance	Ministry of Health and Welfare, Food and Drug Administration/As needed Financial Supervisory Commission/As needed Over-the-counter Trading Center/As needed Official Documents, Regulatory Briefing Sessions/As needed Head of Administration & Finance, Ms. Chang sarahchang@senhwabio.com
Employees	Employees are the foundation of the company’s operations. The company is committed to providing a workplace that supports the physical and mental health of employees and offers diverse development opportunities, ensuring they can work with peace of mind.	Ethics and Integrity Business Performance Compensation and Benefits Labor Relations Occupational Health and Safety	Internal Website/As needed Phone, Email/As needed Training/As needed HR Dept., Ms. Cheng peggycheng@senhwabio.com
Customers	Customers are the main source of the company’s revenue. The company considers product quality, safety, and after-sales service as its highest commitments to customers. Maintaining high customer satisfaction helps the company continue to gain customer recognition.	Product Quality and Safety Drug Sales Status	Phone, Email Company Visits Regular/As needed Meetings Business Development, Mr. Hsu taylorhsu@senhwabio.com
Suppliers/Contractors	The company maintains long-term, positive interactions with suppliers. Our products and services depend on a stable supply of raw materials and components. Additionally, leveraging the company’s influence in the industry, we work with suppliers to avoid environmental pollution and violations of labor rights.	cGMP Guidelines for Product Quality and Safety Environmental Protection and Pollution Prevention	Phone, Email/As needed Supplier Visits/As needed Head of Administration & Finance, Ms. Chang sarahchang@senhwabio.com
Media	The media represents public feedback and suggestions for the company, which motivate the company to continue improving.	R&D Progress Business Expansion and Product Licensing Financial Status Company Development Plans	Press Conferences/As needed Press Releases/As needed Company Website/As needed PR Relations, Ms. Chang gwenchang@senhwabio.com